Case Report: Zinc deficiency as a modifiable risk factor for enfortumab vedotin–induced cutaneous adverse events

Zinc deficiency may represent a modifiable factor in EV-induced skin toxicity, particularly SDRIFE-like rash. Monitoring zinc status and considering supplementation could help mitigate rash severity and support treatment adherence and continuity, which is critical for patients with advanced urothelial carcinoma receiving EV as one of the last available treatment options.